Back to discover
Drug

Tenofovir alafenamide fumarate

Approved · EMA
Late-stage development
Also known as Biktarvy, Descovy, Genvoya, Odefsey+3 more

Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Vemlidy, tenofovir alafenamide (as fumarate).

3
Active clinical trials
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Vemlidy (EMA)

Regulatory2017-01-09EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Tenofovir alafenamide fumarate
Aliases & brands
BiktarvyDescovyGenvoyaOdefseySymtuzaVemlidytenofovir alafenamide (as fumarate)
RxNorm CUI
1721604
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2017-01-09
Latest approval
2017-01-09
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2017-01-09Approval
Approval: Vemlidy (EMA)

Indication: Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1).

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
3
Active studies
2
Recruiting
5
Late-stage (III+)
5
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 1 / 21Phase 22Phase 42Phase N / A3

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.